Here’s our fortnightly wrap of all the news driving ASX health stocks.
It’s been a largely positive two week in the ASX small and mid-cap healthcare space, with 67 companies gaining ground and 49 losing it. Another 16 companies were flat and we had one debutant that we’ll get to later.
Code Company Price % return since Feb 3 %YTD return % return since 31/12/19 MktCap 1AD Adalta 18.5 48.0 119.7 48.0 $47,809,291 1ST 1St Group 3.5 16.7 -39.7 2.9 $15,710,825 4DX 4Dmedical 195 -5.8 -19.8 $346,105,648 AC8 Auscann Grp Hlgs 18 0.0 -33.3 -7.7 $58,653,761 ACR Acrux 17.5 -7.9 2.9 6.1 $49,407,663 ACW Actinogen Medical 2.2 4.8 -27.6 4.8 $35,468,317 ADO Anteotech 26 40.5 815.6 147.6 $523,641,076 ADR Adherium 2.2 0.0 -29.0 -21.4 $14,271,516 AGH Althea Group 53.75 14.4 45.3 23.6 $140,369,844 AHC Austco Healthcare 9.8 -2.0 -6.7 -1.0 $27,850,517 AHK Ark Mines 3.4 0.0 0.0 0.0 $1,778,920 ALC Alcidion Group 21 -2.3 -4.5 13.5 $203,092,281 ALT Analytica 0.3 -25.0 0.0 0.0 $10,558,837 AMT Allegra Orthopaedics 30 -10.4 114.3 -14.3 $31,860,057 ANP Antisense Therapeut. 19.5 5.4 174.6 50.0 $114,811,188 APH AP Hemp 49 8.9 276.9 44.1 $27,762,142 ARX Aroa Biosurgery 120.5 -1.2 4.8 $354,857,169 AT1 Atomo Diagnostics 28.5 -3.4 -6.6 $114,209,294 ATH Alterity Therap 4.3 19.4 152.9 38.7 $89,612,717 ATX Amplia Therapeutics 28.5 5.6 208.1 18.8 $29,084,190 AVE Avecho Biotech 2.5 0.0 614.3 -13.8 $41,571,262 BD1 Bard1 Life Sciences 325 470.2 209.5 377.9 $295,325,756 BIT Biotron 7.3 0.0 -45.9 -6.4 $53,346,886 BNO Bionomics 26.5 82.8 332.5 82.8 $172,783,174 BOT Botanix Pharma 13.25 -22.1 47.2 6.0 $131,374,180 BPH BPH Energy 20.5 -2.4 2263.7 376.7 $83,001,885 BWX BWX 397 -2.9 -13.0 -3.4 $558,175,992 BXN Bioxyne 1.2 0.0 -7.7 0.0 $7,681,745 CAJ Capitol Health 28.5 -1.7 7.3 3.6 $292,822,541 CAN Cann Group 75 15.4 -33.3 27.1 $209,545,966 CBL Control Bionics 73 -7.6 -22.3 $36,085,450 CDX Cardiex 8.7 8.8 278.3 55.4 $76,722,474 CDY Cellmid 9.8 -2.0 -48.4 -10.9 $12,721,230 CGS Cogstate 102.5 -11.4 111.3 -6.8 $168,535,948 CHM Chimeric Therapeutic 30.5 0.0 $56,985,000 CMP Compumedics 45.5 -6.2 -48.3 -9.0 $81,494,956 CP1 Cannpal Animal 18 0.0 44.0 5.9 $17,228,125 CPH Creso Pharma 23 9.5 91.7 27.8 $212,921,938 CTE Cryosite 26.5 -33.8 430.0 -32.9 $12,183,486 CYC Cyclopharm 282 2.5 152.7 12.8 $257,994,297 CYP Cynata Therapeutics 68 2.3 -36.3 -0.7 $98,144,467 DOC Doctor Care Anywhere 128 0.8 6.7 $229,169,496 DVL Dorsavi 3.5 2.9 35.6 -14.6 $12,594,549 DXB Dimerix 29 0.0 100.0 23.4 $56,394,175 EXL Elixinol Global 23 15.0 -54.1 31.4 $73,749,810 EYE Nova EYE Medical 34 3.0 -20.3 -4.2 $48,853,287 FFC Farmaforce 9 0.0 0.0 0.0 $11,589,388 GLH Global Health 40 -5.9 185.7 -14.9 $16,839,328 GSS Genetic Signatures 173.5 -6.7 48.3 -13.7 $257,174,543 GTG Genetic Technologies 1.15 15.0 15.0 53.3 $99,156,494 HCT Holista CollTech 7.1 -1.4 -54.2 -1.4 $19,549,785 HXL Hexima 15 -6.3 -50.8 -18.9 $18,055,861 IBX Imagion Biosys 20 14.3 638.3 37.9 $178,064,289 ICR Intelicare Holdings 28.5 14.0 18.8 $9,893,840 ICS ICSGlobal 196 -0.3 9.0 -7.1 $20,627,077 IDT IDT Australia 21 5.0 50.0 13.5 $50,048,179 IHL annex Healthcare 25 56.3 323.7 61.3 $270,919,222 IMC Immuron 25.5 24.4 82.1 10.9 $55,675,416 IMM Immutep 41 0.0 3.8 -1.2 $272,464,620 IMU Imugene 11 12.2 233.3 10.0 $547,183,357 IPD Impedimed 14.5 20.8 43.1 16.0 $182,010,529 IVX Invion 1.1 22.2 10.0 10.0 $55,377,923 JHC Japara Healthcare Lt 77.5 12.3 -14.1 25.0 $213,797,862 JHL Jayex Healthcare 5 25.0 127.3 28.2 $9,262,699 KZA Kazia Therapeutics 125 -2.3 126.9 7.8 $157,076,999 LBT LBT Innovations 11 4.8 -29.0 -10.2 $31,079,880 LCT Living Cell Tech. 2.1 40.0 10.5 50.0 $12,571,702 LSH Lifespot Health 12.5 8.7 267.9 62.3 $20,216,035 M7T Mach7 Tech 151.5 2.4 80.2 21.2 $366,315,639 MDC Medlab Clinical 32 3.2 4.9 33.3 $95,089,728 MDR Medadvisor 36 -4.0 -30.4 1.4 $129,411,780 MEB Medibio 1 11.1 14.4 25.0 $17,268,733 MEM Memphasys 11 4.8 74.6 10.0 $87,373,996 MMJ MMJ Group Hlds 14 16.7 21.7 12.0 $32,193,558 MVF Monash IVF Group 77.5 -1.9 -13.6 -1.3 $305,863,349 MVP Medical Developments 627 -4.3 -42.6 -6.1 $449,680,080 MX1 Micro-X 36.5 1.4 86.0 2.8 $166,188,326 MXC Mgc Pharmaceuticals 6.7 157.7 148.1 168.0 $173,847,048 NC6 Nanollose 12.5 -3.8 134.2 131.5 $15,489,382 NEU Neuren Pharmaceut. 138 -7.4 -49.6 7.4 $160,451,351 NOX Noxopharm 83 14.5 248.1 69.4 $216,827,148 NSB Neuroscientific 23.5 4.4 46.9 -6.0 $22,626,208 NTI Neurotech Intl 6.7 34.0 737.5 48.9 $34,223,180 NXS Next Science 117.5 -1.3 -43.5 -6.0 $142,590,482 NYR Nyrada . 37.5 10.3 78.6 56.3 $28,254,965 OCC Orthocell 57.5 7.5 18.6 27.8 $108,535,552 OIL Optiscan Imaging 19 72.7 475.8 81.0 $95,483,248 ONE Oneview Healthcare 9.3 14.8 -21.9 106.7 $38,466,264 ONT 1300 Smiles 780 14.4 28.1 15.9 $166,932,607 OPT Opthea 180.75 -5.4 -46.8 -5.9 $611,172,146 OSL Oncosil Medical 11.5 -8.0 -33.0 -4.2 $92,844,479 OSP Osprey Med 1.9 -9.5 18.8 -13.6 $32,466,939 OSX Osteopore 47.5 -5.0 -23.4 -8.7 $36,287,577 OVN Oventus Medical 21 -4.5 -62.8 -10.6 $34,817,732 PAA Pharmaust 10.5 0.0 0.0 0.0 $33,256,642 PAB Patrys 2.6 0.0 45.4 8.3 $48,815,343 PAL Palla Pharma 54 -12.2 -35.7 -33.3 $69,901,127 PAR Paradigm Bio. 261 -6.1 -36.7 2.4 $596,256,007 PBP Probiotec 221 0.0 -6.8 -7.9 $172,619,493 PCK Pahek 7.2 4.3 -40.0 -6.5 $78,876,336 PGC Paragon Care 27 12.5 3.8 20.0 $91,229,029 PIQ Proteomics Int Lab 106.5 43.9 222.7 34.0 $110,151,169 PNV Polynovo 250 -4.6 -18.6 -35.6 $1,679,163,632 PSQ Pacific Smiles Grp 266 1.9 42.8 4.3 $400,675,586 PTX Prescient 12.5 19.0 140.4 86.6 $76,866,361 PXS Pharmaxis 8.5 -1.2 -26.1 -8.6 $34,559,340 PYC PYC Therapeutics 13.5 0.0 112.5 -8.5 $428,075,024 RAC Race Oncology 287 34.7 720.0 64.0 $380,609,093 RAP Resapp Health 6.5 -4.4 -72.9 -23.5 $51,552,125 RCE Recce Pharmaceutical 104.5 2.0 90.0 -0.9 $189,365,237 RGS Regeneus 11 0.0 77.4 -12.0 $33,031,282 RHT Resonance Health 19.5 14.7 -4.9 -18.8 $85,234,376 RHY Rhythm Biosciences 138.5 14.5 1698.7 58.3 $277,159,865 RNO Rhinomed 11.5 -23.3 -28.1 -28.1 $31,726,142 RSH Respiri 13.5 8.0 58.8 3.8 $101,127,711 S66 Star Combo 27.5 -8.3 -52.6 -16.7 $37,045,929 SCU Stemcell United 2.7 58.8 80.0 42.1 $22,688,658 SDI SDI 76 -3.8 -21.8 -3.2 $91,526,458 SHG Singular Health 47 $25,731,750 SOM SomnoMed 186 -2.1 -34.1 -11.4 $158,070,292 SUD Suda Pharmaceuticals 4.9 8.9 3.3 22.5 $18,410,154 SVA Simavita 1.6 -5.9 -30.4 0.0 $22,279,497 TD1 Tali Digital 4.6 12.2 9.5 -2.1 $35,737,550 THC THC Global Grp 25.5 8.5 -33.8 8.5 $48,311,522 TLX Telix Pharmaceutical 419 -1.2 155.5 10.8 $1,163,682,086 TRU Truscreen 9.3 -19.1 $34,835,160 UBI Universal Biosensors 43 -11.3 145.7 -1.1 $76,337,987 VBS Vectus Biosystems 133.5 0.4 130.2 11.3 $41,310,289 VHT Volpara Health Tech 151.5 -1.9 -11.7 5.6 $368,998,049 VLS Vita Life Sciences.. 99.5 4.7 75.0 -0.5 $51,648,894 VTI Vision Tech, 2 17.6 -48.7 -20.0 $19,874,511 ZLD Zelira Therapeutics 8 2.6 37.9 -13.0 $94,825,837 ZNO Zoono Group 74.5 -24.7 -59.9 -43.3 $129,649,039
Bard1 Life Sciences (ASX:BD1) has been by far the biggest gainer since February 3, with shares in the cancer diagnostic company up 470 per cent through yesterday afternoon to $3.25.
At the beginning of the month, BD1 shares were changing hands for less than 60c – and had been in decline for the past 12 months – but have rocketed higher in recent days after the company released data showing its cancer detection tech works against breast cancer and ovarian cancer.
“Obviously we’ve accomplished a lot in a week,” Bard1 chief executive Dr Learnne Hinch joked to Stockhead.
In reality, not much has changed with the company recently, she added. Staff have been hard at work for months “building the foundations for our success” — developing Bard1’s cancer-detecting blood tests and integrating technology from Sienna Cancer Diagnostics after last year’s merger.
“We think we have been substantially undervalued, and the market is finally recognising our value,” she said.
The company is focused on early cancer detection through simple, cost-effective blood tests that could save lives.
“Our multi-product pipeline covers some of the world’s most common and deadliest cancers in multi-billion dollar markets for ovarian, breast, prostate, and pancreatic cancers,” Dr Hinch wrote in an email.
Bard1 has a number of potential value inflection points coming up, including registering its hTERT cancer blood test in South Korea this quarter, and launching its exosome purification platform next quarter.
“We’ve got a lot going on as a business, it’s going be an exciting year for Bard1 and shareholders,” Dr Hinch said.
MGC, Bionomics, Cryosite
The second spot belongs to MGC Pharmaceuticals (ASX:MXC), whose shares soared after MGC became the first cannabis company to list on the London Stock Exchange.
MGC shares have retreated a bit after touching 8c earlier this week, trading for 6.7c yesterday afternoon, still up 157.7 per cent for the fortnight.
Bionomics (ASX:BNO) was in third with an 82 per cent gain, to 26.5c. The company held a $16 million capital raising last week at 14.5c a share to fund a phase 2b clinical trial of its drug candidate to treat post-traumatic stress disorder (PTSD).
On the flip side, Cryosite (ASX:CTE) shares are down by a third, to 26.5c, over the fortnight.
The clinical trials company has released no news, but ASX documents show that a major shareholder has been selling down its holdings.
Blood and tissue bank Cell Care Australia sold over half a million shares over the period, reducing its stake in Cryosite to 18.6 per cent, from 19.7 per cent.
New entrant
Meanwhile, medical imaging company Singular Health (ASX:SHG) has done well after joining the small-cap healthcare space last Friday after a $6 million IPO at 20c a share.
Its shares closed Wednesday at 45c, and changed hands on Tuesday for as much as 55c.